SCHEMBL1242474

SCHEMBL1242474

CCCOc1ccc(N(Cc2ccc(C(C)(C)C)cc2)C(=O)C(=O)OC)c(-c2ccc(OC(F)(F)F)cc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 4/20 0.42
EPHX2 P34913 1/20 0.42
GCGR P47871 2/20 0.40
GIPR P48546 2/20 0.40
GLP1R P43220 1/20 0.40
SERPINE1 P05121 4/20 0.39
TRPV1 Q8NER1 1/20 0.37
CACNA1H O95180 1/20 0.37
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PTGDR2 Q9Y5Y4 2/20 0.36
CYP2C9 P11712 2/20 0.36
FFAR1 O14842 2/20 0.36
FFAR4 Q5NUL3 2/20 0.36
CYP2C8 P10632 1/20 0.36
CYP2C19 P33261 1/20 0.36
SCN5A Q14524 1/20 0.36
VNN1 O95497 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
LTB4R2 Q9NPC1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1239796 0.91 SERPINE1 (0.48) NR1H4EPHX2GCGRGIPRGLP1R
SCHEMBL1242531 0.88 SERPINE1 (0.46) NR1H4EPHX2GCGRGIPRGLP1R
SCHEMBL1241696 0.88 NR1H4 (0.42) NR1H4EPHX2GCGRGIPRGLP1R
SCHEMBL1242698 0.88 NR1H4 (0.43) NR1H4EPHX2GCGRGIPRGLP1R
SCHEMBL15434075 0.88 NR1H4 (0.44) NR1H4EPHX2GCGRGIPRGLP1R
SCHEMBL1242319 0.87 GCGR (0.44) NR1H4EPHX2GCGRGIPRGLP1R
SCHEMBL1242456 0.87 GCGR (0.44) NR1H4EPHX2GCGRGIPRGLP1R
SCHEMBL1242896 0.86 NR1H4 (0.42) NR1H4EPHX2GCGRGIPRGLP1R
SCHEMBL1241602 0.85 SERPINE1 (0.43) NR1H4EPHX2GCGRGIPRGLP1R
SCHEMBL1241505 0.85 SERPINE1 (0.47) NR1H4EPHX2GCGRGIPRGLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633245-B2 PAI-1 inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2014-01-21 US disclosed
US-7884234-B2 N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-02-08 US disclosed
US-7884234-B2 N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-02-08 US disclosed
US-20090312315-A1 PAI-1 INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-17 US disclosed
US-20090215899-A9 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-08-27 US disclosed
US-20090215899-A9 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-08-27 US disclosed
EP-2072498-A1 N-PHENYLOXAMIDIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-06-24 EP disclosed
US-20080249175-A1 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-10-09 US disclosed
US-20080249175-A1 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249175-A1 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 NR1H4 4184/4885EPHX2 958/4885GCGR 1724/4885
US-20090215899-A9 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 NR1H4 4184/4885EPHX2 958/4885GCGR 1724/4885
US-20090312315-A1 PAI-1 INHIBITOR SERPINC1, SERPINE1, SERPINH1 NR1H4 2901/4885EPHX2 1824/4885GCGR 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.